Vyne Therapeutics Inc ( (VYNE) ) has released its Q1 earnings. Here is a breakdown of the information Vyne Therapeutics Inc presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops therapies for chronic inflammatory and immune-mediated conditions, focusing on unmet medical needs with its proprietary BET inhibitors.
In its first quarter of 2025, VYNE Therapeutics reported a net loss of $8.6 million, with revenues totaling $0.2 million. The company is advancing its Phase 2b trial for repibresib gel, targeting vitiligo, with results expected mid-year, while addressing a clinical hold on its VYN202 psoriasis trial.
Key financial highlights include a cash position of $50.3 million, expected to sustain operations into the second half of 2026. Research and development expenses increased to $6.1 million, driven by ongoing trials, while general and administrative expenses decreased slightly to $3.3 million.
Looking ahead, VYNE Therapeutics remains focused on progressing its clinical trials and resolving the clinical hold on VYN202, with a strategic emphasis on addressing significant unmet needs in dermatology and immunology.